Deucravacitinib is a selective tyrosine kinase 2 (TYK2) inhibitor indicated for the treatment of moderate-to-severe plaque psoriasis in adult patients. By modulating the JAK-STAT signaling pathway, this… Read more
Deucravacitinib is a selective tyrosine kinase 2 (TYK2) inhibitor indicated for the treatment of moderate-to-severe plaque psoriasis in adult patients. By modulating the JAK-STAT signaling pathway, this therapeutic agent effectively regulates immune responses associated with chronic skin conditions. This category provides a comprehensive selection of high-quality analytical tools for pharmaceutical laboratories engaged in drug development and rigorous quality control. It includes reference standards for the Deucravacitinib active pharmaceutical ingredient (API), alongside a curated range of non-pharmacopeial impurities and metabolites essential for precise impurity profiling. Additionally, the collection features stable isotope labelled compounds, which are critical as internal standards for mass spectrometry and method validation in complex bioanalytical assays. These materials ensure consistent, reliable results during stability testing and regulatory analysis of therapeutic formulations throughout the drug development lifecycle.